Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Attention Deficit Hyperactivity Disorder
Dopamine transporter genotype affects methylphenidate efficacy
August 15th, 2005
Dopamine transporter (DAT) genotype influences the response to methylphenidate treatment in children with attention deficit hyperactivity disorder (ADHD). "Stimulant medications, such as methylphenidate (MPH), are the most commonly used, effective treatment for ADHD," researchers in the United States explained. "MPH acts primarily by inhibiting" the DAT, "a protein responsible for the reuptake of dopamine from the synapse into presynaptic terminals." In their study, M.A. Stein and coauthors at the University of Chicago "sought to evaluate the relationship between DAT1 3'-untranslated region (3'-UTR) variable number tandem repeats (VNTR) genotypes and...
Source: Pharma Business Week (2005-08-15)
|
